Wall Street analysts forecast that Spark Therapeutics Inc (NASDAQ:ONCE) will report sales of $9.53 million for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Spark Therapeutics’ earnings, with estimates ranging from $1.50 million to $21.30 million. Spark Therapeutics reported sales of $16.30 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 41.5%. The company is expected to issue its next earnings results on Wednesday, February 28th.
According to Zacks, analysts expect that Spark Therapeutics will report full year sales of $9.53 million for the current fiscal year, with estimates ranging from $4.66 million to $25.96 million. For the next year, analysts expect that the business will report sales of $77.06 million per share, with estimates ranging from $3.42 million to $223.80 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Spark Therapeutics.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The business’s revenue was up 45.8% on a year-over-year basis. During the same period last year, the company posted ($1.07) earnings per share.
Shares of Spark Therapeutics (NASDAQ ONCE) traded up $0.71 during trading hours on Friday, hitting $51.26. 553,057 shares of the stock traded hands, compared to its average volume of 1,610,000. The company has a market capitalization of $1,920.00 and a P/E ratio of -7.12. Spark Therapeutics has a 52-week low of $41.06 and a 52-week high of $91.75.
In related news, insider Daniel Faga sold 7,500 shares of the business’s stock in a transaction dated Tuesday, October 24th. The shares were sold at an average price of $80.96, for a total transaction of $607,200.00. Following the transaction, the insider now owns 6,000 shares in the company, valued at $485,760. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Barge Joseph La sold 5,500 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $71.44, for a total transaction of $392,920.00. Following the completion of the sale, the insider now owns 8,146 shares in the company, valued at approximately $581,950.24. The disclosure for this sale can be found here. Insiders have sold 56,309 shares of company stock worth $4,141,385 in the last quarter. 7.30% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its holdings in Spark Therapeutics by 15.0% in the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after purchasing an additional 241,016 shares during the period. Ameriprise Financial Inc. grew its holdings in Spark Therapeutics by 6.0% in the third quarter. Ameriprise Financial Inc. now owns 207,360 shares of the biotechnology company’s stock worth $18,489,000 after purchasing an additional 11,785 shares during the period. BlackRock Inc. grew its holdings in Spark Therapeutics by 11.6% in the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after purchasing an additional 213,520 shares during the period. Amundi Pioneer Asset Management Inc. purchased a new stake in Spark Therapeutics in the third quarter worth about $5,286,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Spark Therapeutics in the third quarter worth about $13,519,000. Institutional investors and hedge funds own 94.91% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://stocknewstimes.com/2018/01/20/9-53-million-in-sales-expected-for-spark-therapeutics-inc-once-this-quarter.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.